International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease.

Evangelos Terpos, Gareth Morgan, Meletios A. Dimopoulos, Matthew T. Drake, Suzanne Lentzsch, Noopur Raje, Orhan Sezer, Ramón García-Sanz, Kazuyuki Shimizu, Ingemar Turesson, Tony Reiman, Artur Jurczyszyn, Giampaolo Merlini, Andrew Spencer, Xavier Leleu, Michele Cavo, Nikhil Munshi, S. Vincent Rajkumar, Brian G M Durie, G. David Roodman

Research output: Contribution to journalArticle

187 Citations (Scopus)

Abstract

The aim of the International Myeloma Working Group was to develop practice recommendations for the management of multiple myeloma (MM) -related bone disease. An interdisciplinary panel of clinical experts on MM and myeloma bone disease developed recommendations based on published data through August 2012. Expert consensus was used to propose additional recommendations in situations where there were insufficient published data. Levels of evidence and grades of recommendations were assigned and approved by panel members. Bisphosphonates (BPs) should be considered in all patients with MM receiving first-line antimyeloma therapy, regardless of presence of osteolytic bone lesions on conventional radiography. However, it is unknown if BPs offer any advantage in patients with no bone disease assessed by magnetic resonance imaging or positron emission tomography/computed tomography. Intravenous (IV) zoledronic acid (ZOL) or pamidronate (PAM) is recommended for preventing skeletal-related events in patients with MM. ZOL is preferred over oral clodronate in newly diagnosed patients with MM because of its potential antimyeloma effects and survival benefits. BPs should be administered every 3 to 4 weeks IV during initial therapy. ZOL or PAM should be continued in patients with active disease and should be resumed after disease relapse, if discontinued in patients achieving complete or very good partial response. BPs are well tolerated, but preventive strategies must be instituted to avoid renal toxicity or osteonecrosis of the jaw. Kyphoplasty should be considered for symptomatic vertebral compression fractures. Low-dose radiation therapy can be used for palliation of uncontrolled pain, impending pathologic fracture, or spinal cord compression. Orthopedic consultation should be sought for long-bone fractures, spinal cord compression, and vertebral column instability.

Original languageEnglish (US)
Pages (from-to)2347-2357
Number of pages11
JournalJournal of Clinical Oncology
Volume31
Issue number18
DOIs
StatePublished - Jun 20 2013

Fingerprint

zoledronic acid
Bone Diseases
Multiple Myeloma
pamidronate
Diphosphonates
Spinal Cord Compression
Therapeutics
Kyphoplasty
Clodronic Acid
Compression Fractures
Spontaneous Fractures
Osteonecrosis
Practice Management
Bone Fractures
Jaw
Radiography
Orthopedics
Consensus
Spine
Radiotherapy

ASJC Scopus subject areas

  • Medicine(all)

Cite this

International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease. / Terpos, Evangelos; Morgan, Gareth; Dimopoulos, Meletios A.; Drake, Matthew T.; Lentzsch, Suzanne; Raje, Noopur; Sezer, Orhan; García-Sanz, Ramón; Shimizu, Kazuyuki; Turesson, Ingemar; Reiman, Tony; Jurczyszyn, Artur; Merlini, Giampaolo; Spencer, Andrew; Leleu, Xavier; Cavo, Michele; Munshi, Nikhil; Rajkumar, S. Vincent; Durie, Brian G M; Roodman, G. David.

In: Journal of Clinical Oncology, Vol. 31, No. 18, 20.06.2013, p. 2347-2357.

Research output: Contribution to journalArticle

Terpos, E, Morgan, G, Dimopoulos, MA, Drake, MT, Lentzsch, S, Raje, N, Sezer, O, García-Sanz, R, Shimizu, K, Turesson, I, Reiman, T, Jurczyszyn, A, Merlini, G, Spencer, A, Leleu, X, Cavo, M, Munshi, N, Rajkumar, SV, Durie, BGM & Roodman, GD 2013, 'International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease.', Journal of Clinical Oncology, vol. 31, no. 18, pp. 2347-2357. https://doi.org/10.1200/JCO.2012.47.7901
Terpos, Evangelos ; Morgan, Gareth ; Dimopoulos, Meletios A. ; Drake, Matthew T. ; Lentzsch, Suzanne ; Raje, Noopur ; Sezer, Orhan ; García-Sanz, Ramón ; Shimizu, Kazuyuki ; Turesson, Ingemar ; Reiman, Tony ; Jurczyszyn, Artur ; Merlini, Giampaolo ; Spencer, Andrew ; Leleu, Xavier ; Cavo, Michele ; Munshi, Nikhil ; Rajkumar, S. Vincent ; Durie, Brian G M ; Roodman, G. David. / International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease. In: Journal of Clinical Oncology. 2013 ; Vol. 31, No. 18. pp. 2347-2357.
@article{7ed2ae5483ed4f4b83530c8ef19da77d,
title = "International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease.",
abstract = "The aim of the International Myeloma Working Group was to develop practice recommendations for the management of multiple myeloma (MM) -related bone disease. An interdisciplinary panel of clinical experts on MM and myeloma bone disease developed recommendations based on published data through August 2012. Expert consensus was used to propose additional recommendations in situations where there were insufficient published data. Levels of evidence and grades of recommendations were assigned and approved by panel members. Bisphosphonates (BPs) should be considered in all patients with MM receiving first-line antimyeloma therapy, regardless of presence of osteolytic bone lesions on conventional radiography. However, it is unknown if BPs offer any advantage in patients with no bone disease assessed by magnetic resonance imaging or positron emission tomography/computed tomography. Intravenous (IV) zoledronic acid (ZOL) or pamidronate (PAM) is recommended for preventing skeletal-related events in patients with MM. ZOL is preferred over oral clodronate in newly diagnosed patients with MM because of its potential antimyeloma effects and survival benefits. BPs should be administered every 3 to 4 weeks IV during initial therapy. ZOL or PAM should be continued in patients with active disease and should be resumed after disease relapse, if discontinued in patients achieving complete or very good partial response. BPs are well tolerated, but preventive strategies must be instituted to avoid renal toxicity or osteonecrosis of the jaw. Kyphoplasty should be considered for symptomatic vertebral compression fractures. Low-dose radiation therapy can be used for palliation of uncontrolled pain, impending pathologic fracture, or spinal cord compression. Orthopedic consultation should be sought for long-bone fractures, spinal cord compression, and vertebral column instability.",
author = "Evangelos Terpos and Gareth Morgan and Dimopoulos, {Meletios A.} and Drake, {Matthew T.} and Suzanne Lentzsch and Noopur Raje and Orhan Sezer and Ram{\'o}n Garc{\'i}a-Sanz and Kazuyuki Shimizu and Ingemar Turesson and Tony Reiman and Artur Jurczyszyn and Giampaolo Merlini and Andrew Spencer and Xavier Leleu and Michele Cavo and Nikhil Munshi and Rajkumar, {S. Vincent} and Durie, {Brian G M} and Roodman, {G. David}",
year = "2013",
month = "6",
day = "20",
doi = "10.1200/JCO.2012.47.7901",
language = "English (US)",
volume = "31",
pages = "2347--2357",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "18",

}

TY - JOUR

T1 - International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease.

AU - Terpos, Evangelos

AU - Morgan, Gareth

AU - Dimopoulos, Meletios A.

AU - Drake, Matthew T.

AU - Lentzsch, Suzanne

AU - Raje, Noopur

AU - Sezer, Orhan

AU - García-Sanz, Ramón

AU - Shimizu, Kazuyuki

AU - Turesson, Ingemar

AU - Reiman, Tony

AU - Jurczyszyn, Artur

AU - Merlini, Giampaolo

AU - Spencer, Andrew

AU - Leleu, Xavier

AU - Cavo, Michele

AU - Munshi, Nikhil

AU - Rajkumar, S. Vincent

AU - Durie, Brian G M

AU - Roodman, G. David

PY - 2013/6/20

Y1 - 2013/6/20

N2 - The aim of the International Myeloma Working Group was to develop practice recommendations for the management of multiple myeloma (MM) -related bone disease. An interdisciplinary panel of clinical experts on MM and myeloma bone disease developed recommendations based on published data through August 2012. Expert consensus was used to propose additional recommendations in situations where there were insufficient published data. Levels of evidence and grades of recommendations were assigned and approved by panel members. Bisphosphonates (BPs) should be considered in all patients with MM receiving first-line antimyeloma therapy, regardless of presence of osteolytic bone lesions on conventional radiography. However, it is unknown if BPs offer any advantage in patients with no bone disease assessed by magnetic resonance imaging or positron emission tomography/computed tomography. Intravenous (IV) zoledronic acid (ZOL) or pamidronate (PAM) is recommended for preventing skeletal-related events in patients with MM. ZOL is preferred over oral clodronate in newly diagnosed patients with MM because of its potential antimyeloma effects and survival benefits. BPs should be administered every 3 to 4 weeks IV during initial therapy. ZOL or PAM should be continued in patients with active disease and should be resumed after disease relapse, if discontinued in patients achieving complete or very good partial response. BPs are well tolerated, but preventive strategies must be instituted to avoid renal toxicity or osteonecrosis of the jaw. Kyphoplasty should be considered for symptomatic vertebral compression fractures. Low-dose radiation therapy can be used for palliation of uncontrolled pain, impending pathologic fracture, or spinal cord compression. Orthopedic consultation should be sought for long-bone fractures, spinal cord compression, and vertebral column instability.

AB - The aim of the International Myeloma Working Group was to develop practice recommendations for the management of multiple myeloma (MM) -related bone disease. An interdisciplinary panel of clinical experts on MM and myeloma bone disease developed recommendations based on published data through August 2012. Expert consensus was used to propose additional recommendations in situations where there were insufficient published data. Levels of evidence and grades of recommendations were assigned and approved by panel members. Bisphosphonates (BPs) should be considered in all patients with MM receiving first-line antimyeloma therapy, regardless of presence of osteolytic bone lesions on conventional radiography. However, it is unknown if BPs offer any advantage in patients with no bone disease assessed by magnetic resonance imaging or positron emission tomography/computed tomography. Intravenous (IV) zoledronic acid (ZOL) or pamidronate (PAM) is recommended for preventing skeletal-related events in patients with MM. ZOL is preferred over oral clodronate in newly diagnosed patients with MM because of its potential antimyeloma effects and survival benefits. BPs should be administered every 3 to 4 weeks IV during initial therapy. ZOL or PAM should be continued in patients with active disease and should be resumed after disease relapse, if discontinued in patients achieving complete or very good partial response. BPs are well tolerated, but preventive strategies must be instituted to avoid renal toxicity or osteonecrosis of the jaw. Kyphoplasty should be considered for symptomatic vertebral compression fractures. Low-dose radiation therapy can be used for palliation of uncontrolled pain, impending pathologic fracture, or spinal cord compression. Orthopedic consultation should be sought for long-bone fractures, spinal cord compression, and vertebral column instability.

UR - http://www.scopus.com/inward/record.url?scp=84883021288&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84883021288&partnerID=8YFLogxK

U2 - 10.1200/JCO.2012.47.7901

DO - 10.1200/JCO.2012.47.7901

M3 - Article

C2 - 23690408

AN - SCOPUS:84883021288

VL - 31

SP - 2347

EP - 2357

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 18

ER -